**Author details**

Courtney Griffiths1 , Michelle Bilbao1 , Lauren Krill1 and Olga Ostrovsky2 \*

1 Department of Gynecologic Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA

2 Department of Surgical Research, Cooper University Health Care, Camden, NJ, USA

\*Address all correspondence to: ostrovsky-olga@cooperhealth.edu

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**245**

*Novel Indications of Epigenetic Therapy in Ovarian Cancer*

[10] Vasey PA. Resistance to

3(Suppl 3):S23-8. doi:10.1038/

[11] Liu MX, Chan D, Ngan H. Gynecology & Obstetrics. *Gynecol Obstet*. Published online 2012:2-5. doi:10.4172/2161-0932.1000e104

[12] Lalwani N, Fasih N. Histologic , Molecular , and Cytogenetic Fea- tures of Ovarian Cancers : Implications for Diagno- sis and Treatment 1. Published

[13] Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. *Med electron Microsc Off J Clin Electron Microsc Soc Japan*. 2003;36(1):9-

[14] Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. *J Ovarian Res*.

[15] Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. *Int J Mol Sci*. 2016;17(12).

17. doi:10.1007/s007950300002

sj.bjc.6601497

online 2011.

2010;3(1):1-11.

doi:10.1186/1757-2215-3-8

doi:10.3390/ijms17122113

[16] Manchana T, Phoolcharoen N, Tantbirojn P. BRCA mutation in high grade epithelial ovarian cancers. *Gynecol Oncol Reports*. 2019;29(April):102-105.

[17] Liu, D., Zhang, XX., Li, MC. *et al.* C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. *Nat Commun* **9,** 1739 (2018). https://doi.org/10.1038/

doi:10.1016/j.gore.2019.07.007

s41467-018-03590-5

chemotherapy in advanced ovarian cancer: mechanisms and current strategies. *Br J Cancer*. 2003;89 Suppl

*DOI: http://dx.doi.org/10.5772/intechopen.98187*

[1] Cancer. CGTCAMA 2nd edition. S

[2] López-Reig R, López-Guerrero JA. The hallmarks of ovarian cancer: proliferation and cell growth. *Eur J Cancer Suppl*. 2020;15:27-37. doi:https:// doi.org/10.1016/j.ejcsup.2019.12.001

[3] Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health*. 2019;11:287-299. doi:10.2147/

[4] Society AC. No Title. Published 2021. https://www.cancer.org/cancer/ovarian-

[5] Brain KE, Smits S, Simon AE, et al. Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample. *BMC Cancer*.

[6] Della Pepa C, Tonini G, Pisano C, et al. Ovarian cancer standard of care: are there real alternatives? *Chin J Cancer*.

[7] Pomel C, Jeyarajah A, Oram D, et al. Cytoreductive surgery in ovarian cancer. *Cancer Imaging*. 2007;7(1):210-215. doi:10.1102/1470-7330.2007.0030

[8] Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy Resistance in Advanced Ovarian Cancer Patients.

cancer/about/key-statistics.html

doi:10.1186/1471-2407-14-171

2015;34(1):17-27. doi:10.5732/

(MA): SA 2000. TD and C of.

**References**

IJWH.S197604

2014;14:171.

cjc.014.10274

*Biomark Cancer*.

1179299X19860815.

2019;11:1179299X19860815-

doi:10.1177/1179299X19860815

[9] Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. *Expert Opin Investig Drugs*. 2010;19(11):1339- 1354. doi:10.1517/13543784.2010.515585

*Novel Indications of Epigenetic Therapy in Ovarian Cancer DOI: http://dx.doi.org/10.5772/intechopen.98187*
